Systematic Review and Meta-Analysis of the Sero-Epidemiological Association between Epstein Barr Virus and Multiple Sclerosis

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Almohmeed, Yahya H ^a   Avenell, Alison ^a   Aucott, Lorna ^b   Vickers, Mark A ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY ANTIGEN; EPSTEIN BARR VIRUS ANTIBODY; EPSTEIN BARR VIRUS ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS CAPSID ANTIGEN;

ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CASE CONTROL STUDY; CLINICAL ASSESSMENT; COHORT ANALYSIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; HUMAN; META ANALYSIS (TOPIC); MULTIPLE SCLEROSIS; NEWCASTLE OTTAWA SCALE; RATING SCALE; SEROEPIDEMIOLOGY; SEROPREVALENCE; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DATABASES, BIBLIOGRAPHIC; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN G; MALE; MULTIPLE SCLEROSIS; ODDS RATIO; PUBLICATION BIAS;

HUMAN HERPESVIRUS 4;

EID: 84876028814     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061110     Document Type: Article

References (62)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG, (2000) Multiple sclerosis. N Engl J Med 343: 938-952.
2. Milo R, Kahana E, (2010) Multiple sclerosis: Geoepidemiology, genetics and the environment. Autoimmun Rev 9: A387-94.
3. Multiple Sclerosis Society in England and Wales (2012) Available.:http://www.mssociety.org.uk.
4. Kobelt G, Berg J, Lindgren P, Kerrigan J, Russell N, et al. (2006) Costs and quality of life of multiple sclerosis in the united kingdom. Eur J Health Econ 7: 96-104.
5. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G, (2010) Multiple sclerosis: Risk factors, prodromes, and potential causal pathways. Lancet Neurol 9: 727-739.
6. Kakalacheva K, Munz C, Lunemann JD, (2011) Viral triggers of multiple sclerosis. Biochim Biophys Acta 1812(2): 132-140.
7. Ascherio A, Munger KL, (2007) Environmental risk factors for multiple sclerosis. part I: The role of infection. Ann Neurol 61(4): 288-299.
8. Pakpoor J, Disanto G, Gerber J, Dobson R, Meier U, et al. (2012) The risk of developing multiple sclerosis in individuals seronegative for epstein-barr virus: A meta-analysis. Mult Scler 0(0): 1-5.
9. Pohl D, (2009) Epstein-barr virus and multiple sclerosis. J Neurol Sci 286(1-2): 62-64.
10. Santiago O, Gutierrez J, Sorlozano A, de Dios Luna J, Villegas E, et al. (2010) Relation between epstein-barr virus and multiple sclerosis: Analytic study of scientific production. Eur J Clin Microbiol Infect Dis 29(7): 857-66.
11. Wells G, Shea B, O'Connell D, Peterson J, Welch V, et al. (2011) The newcastle-ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2012(June, 6).Available:http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
12. The Cochrane Collaboration (2011) Review manager (RevMan) [computer program]. version 5.1. Copenhagen: The Nordic Cochrane Centre.
13. Higgins J, Green S, editors (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated march 2011]: The Cochrane Collaboration. Available:www.cochrane-handbook.org.
14. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2): 292-302 Available:http://dx.doi.org/10.1002/ana.22366.
15. Poser C, Paty D, Scheinberg L, McDonald W, Davis F, et al. (1983) New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 13(3): 227-231.
16. Moher D, Liberati A, Tetzlaff J, Altman D, (2009) The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 6(6): e1000097 doi:10.1371/journal.pmed1000097.
17. Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B, (2004) Epstein-barr virus in pediatric multiple sclerosis. JAMA 291(15): 1875-1879.
18. Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernan MA, et al. (2001) Epstein-barr virus antibodies and risk of multiple sclerosis: A prospective study. JAMA 286(24): 3083-3088.
19. Banwell B, Krupp L, Kennedy J, Tellier R, Tenembaum S, et al. (2007) Clinical features and viral serologies in children with multiple sclerosis: A multinational observational study. Lancet Neurol 6(9): 773-81.
20. Bray PF, Bloomer LC, Salmon VC, Bagley MH, Larsen PD, (1983) Epstein-barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch Neurol 40(7): 406-8.
21. Buljevac D, van Doornum GJJ, Flach HZ, Groen J, Osterhaus ADME, et al. (2005) Epstein-barr virus and disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 76(10): 1377-81.
22. Comabella M, Montalban X, Horga A, Messmer B, Kakalacheva K, et al. (2010) Antiviral immune response in patients with multiple sclerosis and healthy siblings. Mult Scler 16(3): 355-358.
23. Ferrante P, Castellani P, Barbi M, Bergamini F, (1987) The italian cooperative multiple sclerosis case-control study: Preliminary results on viral antibodies. Ital J Neurol Sci Suppl 6(6)pp. 45-50.
24. Gutierrez J, Vergara M, Guerrero M, Fernandez O, Piedrola G, et al. (2002) Multiple sclerosis and human herpesvirus 6. Infection 30(3): 145-149.
25. Haahr S, Plesner AM, Vestergaard BF, Hllsberg P, (2004) A role of late epstein-barr virus infection in multiple sclerosis. Acta Neurol Scand 109(4): 270-5.
26. Ingram G, Bugert JJ, Loveless S, Robertson NP, (2010) Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity. Eur J Neurol 17(11): 1386-1389.
27. Jafari N, van Nierop GP, Verjans GMGM, Osterhaus ADME, Middeldorp JM, et al. (2010) No evidence for intrathecal IgG synthesis to epstein barr virus nuclear antigen-1 in multiple sclerosis. J Clin Virol 49(1): 26-31.
28. Jaquiery E, Jilek S, Schluep M, Meylan P, Lysandropoulos A, et al. (2010) Intrathecal immune responses to EBV in early MS. Eur J Immunol 40(3): 878-887.
29. Jilek S, Schluep M, Meylan P, Vingerhoets F, Guignard L, et al. (2008) Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 131(7): 1712-1721.
30. Khaki M, Ghazavi A, Ghasami K, Rafiei M, Payani M, et al. (2011) Evaluation of viral antibodies in iranian multiple sclerosis. Neurosciences (Riyadh) 16(3): 224-228.
31. Lalive PH, Hausler MG, Maurey H, Mikaeloff Y, Tardieu M, et al. (2011) Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler 17(3): 297-302.
32. Larsen PD, Bloomer LC, Bray PF, (1985) Epstein-barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology 35(3): 435-8.
33. Levin LI, Munger KL, O'Reilly EJ, Falk KI, Ascherio A, (2010) Primary infection with the epstein-barr virus and risk of multiple sclerosis. Ann Neurol 67(6): 824-830.
34. Lindsey JW, Hatfield LM, Vu T, (2010) Epstein-barr virus neutralizing and early antigen antibodies in multiple sclerosis. Eur J Neurol 17(10): 1263-1269.
35. Lucas RM, Ponsonby A, Dear K, Valery P, Pender MP, et al. (2011) Current and past epstein-barr virus infection in risk of initial CNS demyelination. Neurology 77(4): 371-379.
36. Martyn CN, Cruddas M, Compston DAS, (1993) Symptomatic epstein-barr virus infection and multiple sclerosis. J Neurol Neurosurg Psychiatry 56(2): 167-168.
37. Mowry EM, James JA, Krupp LB, Waubant E, (2011) Vitamin D status and antibody levels to common viruses in pediatric-onset multiple sclerosis. Mult Scler 17(6): 666-671.
38. Munch M, Riisom K, Christensen T, Mller-Larsen A, Haahr S, (1998) The significance of epstein-barr virus seropositivity in multiple sclerosis patients. Acta Neurol Scand 97(3): 171-4.
39. Myhr KM, Riise T, Barrett Connor E, Myrmel H, Vedeler C, et al. (1998) Altered antibody pattern to epstein-barr virus but not to other herpesviruses in multiple sclerosis: A population based case-control study from western norway. J Neurol Neurosurg Psychiatry 64(4): 539-42.
40. Nociti V, Frisullo G, Marti A, Luigetti M, Iorio R, et al. (2010) Epstein-barr virus antibodies in serum and cerebrospinal fluid from multiple sclerosis, chronic inflammatory demyelinating polyradiculoneuropathy and amyotrophic lateral sclerosis. J Neuroimmunol 225(1-2)(pp 149-152).
41. Pohl D, Krone B, Rostasy K, Kahler E, Brunner E, et al. (2006) High seroprevalence of epstein-barr virus in children with multiple sclerosis. Neurology 67(11): 2063-2065.
42. Ponsonby AL, van der Mei I, Dwyer T, Blizzard L, Taylor B, et al. (2005) Exposure to infant siblings during early life and risk of multiple sclerosis. JAMA 293(4): 463-469.
43. Riverol M, Sepulcre J, Fernandez Diez B, Villoslada P, Fernandez Alonso M, et al. (2007) Antibodies against epstein-barr virus and herpesvirus type 6 are associated with the early phases of multiple sclerosis. J Neuroimmunol 192(1-2): 184-5.
44. Sellner J, Cepok S, Kalluri SR, Nestler A, Kleiter I, et al. (2010) Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses. Neurochem Int 57(6): 662-667.
45. Selter RC, Brilot F, Grummel V, Kraus V, Cepok S, et al. (2010) Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases. Neurology 74(21): 1711-1715.
46. Shirodaria PV, Haire M, Fleming E, Merrett JD, Hawkins SA, et al. (1987) Viral antibody titers. comparison in patients with multiple sclerosis and rheumatoid arthritis. Arch Neurol 44(12): 1237-41.
47. Sumaya CV, Myers LW, Ellison GW, (1980) Epstein-barr virus antibodies in multiple sclerosis. Arch Neurol 37(2): 94-6.
48. Sumaya CV, Myers LW, Ellison GW, Ench Y, (1985) Increased prevalence and titer of epstein-barr virus antibodies in patients with multiple sclerosis. Ann Neurol 17(4): 371-7.
49. Sundqvist E, Sundstrom P, Linden M, Hedstrom AK, Aloisi F, et al. (2012) Epstein-barr virus and multiple sclerosis: Interaction with HLA. Genes Immun 13(1): 14-20.
50. Sundstrom P, Juto P, Wadell G, Hallmans G, Svenningsson A, et al. (2004) An altered immune response to epstein-barr virus in multiple sclerosis: A prospective study. Neurology 62(12): 2277-2282.
51. Villegas E, Santiago O, Carrillo JA, Sorlozano A, Guerrero M, et al. (2011) Low intrathecal immune response of anti-EBNA-1 antibodies and EBV DNA from multiple sclerosis patients. Diagn Microbiol Infect Dis 70(1): 85-90.
52. Villoslada P, Juste C, Tintore M, Llorenc V, Codina G, et al. (2003) The immune response against herpesvirus is more prominent in the early stages of MS. Neurology 60(12): 1944-1948.
53. Wandinger K, Jabs W, Siekhaus A, Bubel S, Trillenberg P, et al. (2000) Association between clinical disease activity and epstein-barr virus reactivation in MS. Neurology 55(2): 178-84.
54. Waubant E, Mowry EM, Krupp L, Chitnis T, Yeh EA, et al. (2011) Common viruses associated with lower pediatric multiple sclerosis risk. Neurology 76(23): 1989-1995.
55. Zivadinov R, Nasuelli D, Tommasi M, Serafin M, Bratina A, et al. (2006) Positivity of cytomegalovirus antibodies predicts a better clinical and radiological outcome in multiple sclerosis patients. Neurol Res 28(3): 262-9.
56. Wagner HJ, Hennig H, Jabs WJ, Siekhaus A, Wessel K, et al. (2000) Altered prevalence and reactivity of anti-epstein-barr virus antibodies in patients with multiple sclerosis. Viral Immunol 13(4): 497-502.
57. Disanto G, Pakpoor J, Morahan J, Hall C, Meier U, et al. (2012) Epstein-Barr virus, latitude and multiple sclerosis. Mult Scler l 0(0): 1-4.
58. Woodward M (1999) Epidemiology: Study design and analysis.USA:Chapman and Hall/CRC.
59. Elm E, Altman D, Egger M, Pocock S, Gøtzsche P, et al. (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Bull World Health Organ 85(11): 867.
60. Ascherio A, Munger KL, (2010) Epstein-barr virus infection and multiple sclerosis: A review. J Neuroimmune Pharmacol 5(3): 271-277.
61. DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, et al. (2006) Epstein-barr virus and multiple sclerosis: Evidence of association from a prospective study with long-term follow-up. Arch Neurol 63(6): 839-844.
62. Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, et al. (2005) Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. J Am Med Assoc 293(20): 2496-2500.